特刊：抗病毒治疗的疗效和安全性
Special Issue "Efficacy and Safety of Antiviral Therapy".
机构信息
Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy.
出版信息
Viruses. 2023 Jun 21;15(7):1411. doi: 10.3390/v15071411.
Abstract
This comprehensive collection of papers contains a wide range of studies and observations centered on antiviral therapies, with a particular focus on HIV and other viral infections such as monkeypox and SARS-CoV-2 [...].
摘要
本论文集广泛收录了有关抗病毒疗法的研究和观察，特别关注 HIV 及猴痘和 SARS-CoV-2 等其他病毒感染。
相似文献
1
Special Issue "Efficacy and Safety of Antiviral Therapy".特刊：抗病毒治疗的疗效和安全性
Viruses. 2023 Jun 21;15(7):1411. doi: 10.3390/v15071411.
2
Advances toward COVID-19 Therapies Special Issue Call for Papers.《COVID-19治疗进展》特刊征稿。
J Med Chem. 2020 Dec 24;63(24):15073-15074. doi: 10.1021/acs.jmedchem.0c01963. Epub 2020 Dec 2.
3
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
4
Lack of antiviral activity of darunavir against SARS-CoV-2.达芦那韦对 SARS-CoV-2 无抗病毒活性。
Int J Infect Dis. 2020 Aug;97:7-10. doi: 10.1016/j.ijid.2020.05.085. Epub 2020 May 29.
5
A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.全面更新的关于 SARS-CoV-2 和 COVID-19 的综述。
J Clin Pharmacol. 2020 Aug;60(8):954-975. doi: 10.1002/jcph.1673. Epub 2020 Jun 24.
6
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.新型冠状病毒治疗药物的安全性、临床应用和抗病毒研究概述。
J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13.
7
Antiviral drugs proposed for COVID-19: action mechanism and pharmacological data.用于 COVID-19 的抗病毒药物：作用机制和药理学数据。
Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):4163-4173. doi: 10.26355/eurrev_202106_26060.
8
A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity.天然类黄酮抗 SARS-CoV-2 活性的综合评价
Molecules. 2023 Mar 17;28(6):2735. doi: 10.3390/molecules28062735.
9
Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview.食物植物次生代谢物的抗病毒活性及其在 SARS-CoV-2 治疗中的可能作用：综述。
Molecules. 2023 Mar 8;28(6):2470. doi: 10.3390/molecules28062470.
10
Novel Binding Mechanisms of Fusion Broad Range Anti-Infective Protein Ricin A Chain Mutant-Pokeweed Antiviral Protein 1 (RTAM-PAP1) against SARS-CoV-2 Key Proteins in Silico.新型融合广谱抗感染蛋白蓖麻毒蛋白 A 链突变体-雀麦抗病毒蛋白 1（RTAM-PAP1）与 SARS-CoV-2 关键蛋白的计算机模拟结合机制。
Toxins (Basel). 2020 Sep 17;12(9):602. doi: 10.3390/toxins12090602.
本文引用的文献
1
Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort.在经病毒学控制的 HIV 感染者中，从比克替拉韦/恩曲他滨/丙酚替诺福韦二吡呋酯转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺富马酸盐后免疫重建和安全代谢特征：来自 BICTEL 队列的 96 周更新。
Viruses. 2023 May 23;15(6):1222. doi: 10.3390/v15061222.
2
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.在初治 AIDS 或晚期 HIV 感染患者中，基于多替拉韦或达芦那韦的方案的疗效和持久性。
Viruses. 2023 May 8;15(5):1123. doi: 10.3390/v15051123.
3
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen.PLWHIV 切换至多伟拉韦方案后代谢特征的变化。
Viruses. 2023 Apr 25;15(5):1046. doi: 10.3390/v15051046.
4
5
Topical Protease Inhibitor Decreases Anal Carcinogenesis in a Transgenic Mouse Model of HPV Anal Disease.局部蛋白酶抑制剂降低 HPV 肛门疾病转基因小鼠模型中的肛门癌发生。
Viruses. 2023 Apr 20;15(4):1013. doi: 10.3390/v15041013.
6
Use of Remdesivir in Patients with SARS-CoV-2 Pneumonia in a Real-Life Setting during the Second and Third COVID-19 Epidemic Waves.在第二波和第三波 COVID-19 疫情期间，在真实环境中使用瑞德西韦治疗 SARS-CoV-2 肺炎患者。
Viruses. 2023 Apr 11;15(4):947. doi: 10.3390/v15040947.
7
Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study.过去 20 年中 HIV 治疗中断的原因：一项多队列真实研究。
Viruses. 2023 Mar 10;15(3):720. doi: 10.3390/v15030720.
8
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics.2022 年 5 月至 10 月期间，意大利米兰一家三级医院的人类猴痘病例：流行病学特征和临床特征。
Viruses. 2023 Mar 2;15(3):667. doi: 10.3390/v15030667.
9
Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study.莫努匹韦和奈玛特韦/利托那韦：一项回顾性队列研究中的耐受性、安全性和依从性。
Viruses. 2023 Jan 28;15(2):384. doi: 10.3390/v15020384.
10
Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study.所有 COVID-19 疾病危重症患者从添加托珠单抗联合糖皮质激素治疗中获益吗？一项回顾性队列研究。
Viruses. 2023 Jan 20;15(2):294. doi: 10.3390/v15020294.
Zotero 插件